List of Phoslyra drug patents

Phoslyra is owned by Fresenius Medcl.

Phoslyra contains Calcium Acetate.

Phoslyra has a total of 3 drug patents out of which 0 drug patents have expired.

Phoslyra was authorised for market use on 18 April, 2011.

Phoslyra is available in solution;oral dosage forms.

Phoslyra can be used as use of phoslyra for reduction of serum phosphorous in patients.

The generics of Phoslyra are possible to be released after 23 February, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592480 FRESENIUS MEDCL Liquid compositions of calcium acetate
Jul, 2027

(4 years from now)

US9089528 FRESENIUS MEDCL Liquid compositions of calcium acetate
Jul, 2027

(4 years from now)

US8591938 FRESENIUS MEDCL Liquid compositions of calcium acetate
Feb, 2030

(7 years from now)

Drugs and Companies using CALCIUM ACETATE ingredient

Market Authorisation Date: 18 April, 2011

Treatment: Use of phoslyra for reduction of serum phosphorous in patients

Dosage: SOLUTION;ORAL

How can I launch a generic of PHOSLYRA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in